Emergent BioSolutions Inc. (NYSE: EBS) closed the day trading at $13.11 down -3.10% from the previous closing price of $13.53. In other words, the price has decreased by -$0.42 from its previous closing price. On the day, 501174 shares were traded. EBS stock price reached its highest trading level at $14.20 during the session, while it also had its lowest trading level at $13.03.
For a better understanding of EBS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.02. For the most recent quarter (mrq), Quick Ratio is recorded 2.10 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.73 whereas as Long-Term Debt/Eq ratio is at 0.71.
Upgrades & Downgrades
The Benchmark Company Upgraded its Hold to Buy on January 20, 2022, while the target price for the stock was maintained at $77.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 when Richard Ronald sold 1,912 shares for $11.94 per share. The transaction valued at 22,829 led to the insider holds 19,837 shares of the business.
Zoon Kathryn C sold 1,173 shares of EBS for $36,973 on Jun 09. The Director now owns 19,654 shares after completing the transaction at $31.52 per share. On May 24, another insider, Zoon Kathryn C, who serves as the Director of the company, sold 1,996 shares for $35.53 each. As a result, the insider received 70,918 and left with 12,381 shares of the company.
As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.99, and their Forward P/E ratio for the next fiscal year is 17.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 0.45.
Stock Price History:
Over the past 52 weeks, EBS has reached a high of $47.71, while it has fallen to a 52-week low of $10.61. The 50-Day Moving Average of the stock is 12.40, while the 200-Day Moving Average is calculated to be 24.64.
Over the past 3-months, EBS traded about 1.01M shares per day on average, while over the past 10 days, EBS traded about 900.33k shares per day. A total of 49.90M shares are outstanding, with a floating share count of 44.81M. Insiders hold about 0.50% of the company’s shares, while institutions hold 84.60% stake in the company. Shares short for EBS as of Oct 13, 2022 were 2.03M with a Short Ratio of 5.57M, compared to 2.05M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.07% and a Short% of Float of 6.45%.
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.06 for the current quarter, with a high estimate of $0.26 and a low estimate of -$0.48, while EPS last year was -$0.36. The consensus estimate for the next quarter is $0.76, with high estimates of $1.06 and low estimates of $0.39.
Analysts are recommending an EPS of between $0.3 and -$0.22 for the fiscal current year, implying an average EPS of $0.02. EPS for the following year is $2.03, with 5 analysts recommending between $5.39 and $0.54.
7 analysts predict $268.3M in revenue for the current quarter. It ranges from a high estimate of $320M to a low estimate of $247M. As of the current estimate, Emergent BioSolutions Inc.’s year-ago sales were $329M, an estimated decrease of -18.40% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $378.53M, a decrease of -47.70% less than the figure of -$18.40% in the same quarter last year. There is a high estimate of $429M for the next quarter, whereas the lowest estimate is $345M.
A total of 7 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $1.25B, while the lowest revenue estimate was $1.16B, resulting in an average revenue estimate of $1.2B. In the same quarter a year ago, actual revenue was $1.79B, down -33.20% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $1.23B in the next fiscal year. The high estimate is $1.28B and the low estimate is $1.13B. The average revenue growth estimate for next year is up 2.90% from the average revenue estimate for this year.